Prothena's anti-amyloid therapy receives FDA fast track designation to treat Alzheimer’s
BioPharma-Reporter - 03-May-2022Guarantees higher efficacy, convenience and potential safety than other anti-Aβ therapies
Join the club for FREE to access the whole archive and other member benefits.
Multimedia journalist and senior editor with William Reed and BioPharma-Reporter
Jane Byrne is a multimedia journalist and senior editor with William Reed and BioPharma-Reporter, writing and producing videos, webinars and podcasts on international food, nutrition, feed and biopharma industry, as well as managing editorial teams, taking the lead in digital innovation and devising and chairing face2face events.
As both a senior editor and communications professional, she has developed online communication campaigns, and built social media communities. Her writings were published in international magazines on various topics from science to literature.
Byrne graduated with BA in English and History from University College Dublin.
Visit website: https://www.feednavigator.com/Info/About-us#Jane_Byrne
See alsoDetails last updated 03-Jul-2023
Guarantees higher efficacy, convenience and potential safety than other anti-Aβ therapies
French biotech Seekyo secures funding for a tumour-targeting chemotherapy drug